Benzinga | Dec 16, 2021 08:08AM EST

Barclays Maintains Overweight on Travere Therapeutics, Raises Price Target to $40

Barclays analyst Carter Gould maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target from $36 to $40.